Saiba Animal Health AG’s executes a license for the development and commercialization of a lead product candidate.

Pfäffikon (SZ) Switzerland 21st of December 2022: Saiba Animal Health AG announced today the achievement of a significant collaboration milestone stemming from a partnership agreement initiated in October 2019. The partner, a leading global animal health company, exercised their option to take an exclusive license for the commercialization and development of one of Saiba’s product candidates.

Dr. Gary T. Jennings, CEO of Saiba Animal Health AG commented: “This significant step in our collaboration was the result of a compelling preclinical data-set generated by the R&D teams of both parties over the course of the initial research agreement. We are very excited at the prospect of the formidable capabilities of our partner being used to advance the product candidate into development and hopefully to the market. Significantly, we consider our partner’s commitment due recognition of the potential of our platform technology to be translated into cost effective therapies for companion animals.”

The license execution also triggered a significant upfront payment which Saiba Animal Health will use to further advance its technology and other pipeline candidates.”

For additional information, please contact:

Saiba Animal Health AG
CH-8808 Pfäffikon (SZ),
Gary Jennings, PhD